Company intelligence / Profile preview

New Valve Technology

Muri, Argau, Switzerlandnvtphybridge.com ↗

Ownership: Private
Development stage: Commercial

Overview

The company developed and commercialized the ALLEGRA™ transcatheter aortic valve system for TAVI procedures. Clinical data from the VIVALL trial showed positive outcomes at 30 days in valve-in-valve settings. The device is CE-marked and used in Europe.

Therapeutic areas: Cardiovascular
Modalities: Device
Industry: Implantable Medical Devices

Partnerships

Biosensors International Group (Blue Sail subsidiary)

Beyond the preview

Go deeper on New Valve Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on New Valve Technology.

Explore the full profile